Table of Contents
- Trial overview
- Study design and treatments
- Who can participate
- What is being measured
- What the results may mean for patients
- Key terms explained
Trial overview
The clinical trial for ZINC is studying zinc acetate dose regimens in relation to Wilson’s disease.[1] It is an interventional study, which means researchers assign the treatments and then measure the effects.[1]
This study is listed as Phase 2 and is authorised.[1] The planned enrollment is 36 participants.[1]
Study design and treatments
The study compares three treatment groups: Galzin 50 mg three times daily, ET-700 75 mg twice daily, and placebo.[1] The trial summary says the goal is to see how these regimens affect intestinal copper absorption in healthy volunteers.[1]
The trial also uses 64Cu PET/CT, a scan method that helps researchers track a copper tracer in the body.[1] In this study, the amount of tracer found in the liver is used as a sign of copper absorption.[1]
Who can participate
The available data say that the study is being done in healthy participants.[1] No other inclusion or exclusion details are provided in the trial record.[1]
This is important because the study is not testing people with Wilson’s disease directly in the provided record.[1] Instead, it is designed to help researchers understand copper absorption under controlled study conditions.[1]
What is being measured
The main endpoint is the change in mean hepatic 64Cu standard uptake value (SUV) from before to after the intervention between the three groups.[1] SUV is a number that shows how much of the tracer is taken up by an organ, here the liver.[1]
Because the liver is a major organ for copper handling, this measurement helps researchers compare how the different regimens affect copper movement in the body.[1] The study summary specifically says the scans are being used to assess intestinal copper absorption by measuring the amount of 64Cu in the liver.[1]
What the results may mean for patients
For patients, this trial is mainly about learning whether different zinc acetate schedules change copper absorption in a measurable way.[1] That information may help build better research knowledge for Wilson’s disease.[1]
The trial does not provide final results in the source data, so it cannot yet show which regimen works best.[1] It does show that researchers are comparing active treatment with placebo and using imaging to measure the effect.[1]
Key terms explained
Wilson’s disease is the condition named in the trial record and is linked to copper handling in the body.[1] Placebo means a look-alike treatment with no active study drug, used for comparison.[1]
Interventional means the researchers give the treatments rather than only observing what happens.[1] Authorised means the study has been approved to start according to the record provided.[1]
Healthy volunteers are people without the disease being studied, and they help researchers make clearer comparisons.[1] Endpoint means the main result the study is designed to measure.[1]
